Highest-materiality recent filing
Seer Board Unanimously Rejects $2.40/Share Cash Plus CVR Bid from Radoff-JEC Group
Board unanimously rejected May 14 revised proposal at $2.40/share cash plus contingent value right.
Seer Q1 2026 revenue $2.8M (-34% YoY); reaffirms FY2026 guidance of $16M-$18M
Revenue $2.8M, down 34% from $4.2M YoY, driven by depressed academic funding and competitive activity.
Seer appoints Anthony Bazarko as Chief Commercial Officer
Anthony Bazarko named CCO effective May 4, 2026; previously President & CEO of Biologos and CCO at Specific Diagnostics.
Seer Board unanimously rejects revised $2.35/share takeover bid from Radoff-JEC Group
Revised proposal from Radoff/JEC offers $2.35/share plus contingent value right; board says significantly undervalues Seer.
Seer receives unsolicited $2.25/share buyout proposal from Radoff-JEC Group
Radoff-JEC Group proposed to acquire all Seer shares for $2.25 per share cash plus a contingent value right.
PTAB upholds 23 claims of Seer's particle proteomics patent in Bruker challenge
PTAB Final Written Decision on March 23, 2026, upholds five challenged and 18 unchallenged claims of U.S. Patent No. 11,435,360.
Seer amends Tax Benefit Preservation Plan, pays $250K mootness fee to settle suit
Amended definition of 'Beneficial Ownership' in Tax Benefit Preservation Plan to address stockholder lawsuit.
Seer Q4 revenue $4.2M (+5% YoY); FY 2026 guidance $16-18M implies ~3% midpoint growth
Q4 2025 revenue $4.2M, up 5% YoY from $4.0M; product revenue $2.8M, service $1.2M.
Seer adopts tax-benefit preservation plan (poison pill) to protect NOLs; triggers at 4.9% ownership
Board declared dividend of one Right per common share, record date March 9, 2026.
Seer converts all Class B stock to Class A, ending dual-class voting
All outstanding Class B shares automatically converted into Class A on a 1:1 basis at close of business Dec. 9, 2025.
Seer Q3 2025 revenue $4.1M, net loss $18.2M; reaffirms FY25 revenue guidance $17-18M
Revenue $4.1M (+2% YoY); product revenue $2.8M, service revenue $1.2M, including $300K related party.
Seer appoints Isaac Ro to Board of Directors; grants initial equity award
Isaac Ro appointed to Seer board effective Sept 2, 2025, also named to Audit Committee as financial expert.
Seer Q2 revenue $4.1M (+32% YoY); launches Proteograph ONE & SP200
Revenue of $4.1M for Q2 2025, up 32% from $3.1M a year ago, driven by product and service revenue.
Seer non-compliant with Nasdaq Audit Committee rule after annual meeting; cure period sought
On July 7, 2025, notified Nasdaq that post-annual meeting it will not comply with Rule 5605(c)(2)(A) requiring at least three Audit Committee members, one with financial sophistication.
Revenue $4.2M, up 37% from $3.1M YoY, driven by higher product sales and service revenue.
Seer Q4 revenue down 10% YoY to $4.0M; full-year net loss $86.6M; guides 2025 rev $17-18M
Q4 2024 revenue $4.0M (-10% YoY); full-year 2024 revenue $14.2M (-15% YoY).
Seer Q3 2024 revenue $4.0M, net loss $21.3M; FY guidance reaffirmed $13-15M
Q3 revenue $4.0M vs $4.2M YoY (down 3%); product revenue $3.1M, service $847K, grant $90K.
Seer reprices ~7.9M underwater options to $2.00; CEO/CFO affected
Board approved repricing of ~7.9M underwater options (original strike $2.08-$60.15) to $2.00 per share.
Seer appoints Nicolas Roelofs to board as Lead Independent Director effective Aug 13, 2024
Roelofs replaces David Hallal as Lead Independent Director and joins CG&N and Science & Technology committees.
Seer Q2 revenue $3.1M (-23% YoY); FY 2024 guidance cut to $13-15M
Revenue $3.1M, down 23% YoY from $4.0M; product revenue $2.2M, service $845K.
Seer CLO resigns; David Hallal appointed to Audit Committee, resolving Nasdaq compliance
Elona Kogan resigns as Chief Legal Officer and Corporate Secretary effective July 26, 2024; departure not related to any disagreement.
Seer director resigns; company out of compliance with Nasdaq Audit Committee rule
Dr. Rachel Haurwitz resigned from Seer's Board and all committees effective July 8, 2024.
Seer stockholders elect four directors and ratify Deloitte as auditor at 2024 annual meeting
Quorum achieved with 82.8M votes representing 81.7% of eligible votes.
Seer Q1 revenue down 24% YoY to $3.1M; net loss narrows to $20.7M; authorizes $25M buyback
Revenue $3.1M (-24% YoY); product revenue $2.5M (incl. $828K related party), service $534K.
Seer reports Q4 revenue down 4% YoY to $4.4M; FY revenue up 8% to $16.7M
Q4 2023 net loss $17.8M narrowed from $22.5M; FY net loss $86.3M vs $93.0M prior year.
On August 13, 2024, the board of directors (the “Board”) of Seer, Inc. (the “Company”) appointed Nicolas Henry Roelofs, Ph.D. to the Board with a term expiring at the Company’s 2025 annual meeting of the stockholders.
The Company also announced that Dr. Roelofs would replace David Hallal as the Company’s Lead Independent Director and would serve on the Company’s Corporate Governance and Nominating Committee and Science and Technology Committee.
On July 16, 2024, Elona Kogan resigned as the Chief Legal Officer and Corporate Secretary of Seer, Inc. (the “Company”), to pursue other career opportunities.
On July 8, 2024, Rachel Haurwitz, Ph.D. informed Seer, Inc. (the “Company”) of her resignation as a member of the Company’s Board of Directors (the “Board”) and all committees thereof, effective immediately
Max materiality 0.80 · Median 0.60 · Most common event earnings